Antennova Unveils New Data on CD73 Inhibitor ATN-037, Showcasing an 89.5% DCR, in a Brief Presentation at ESMO Congress 2024.

GV20 Therapeutics Shares Encouraging Phase 1 Monotherapy Results for New Checkpoint Inhibitor GV20-0251 at 2024 ESMO Congress.

Linnaeus Therapeutics to Present Positive Clinical Results of LNS8801 in Metastatic Melanoma at 2024 ESMO Annual Conference.

Tharimmune Secures Worldwide Rights and Collaborates With Intract Pharma to Create Oral Infliximab.

Coya Therapeutics Reports that Subcutaneously Dosed COYA 302 Shows Direct Anti-Inflammatory Effects in the Brain in a Mouse Model of Parkinson’s Disease.

Dupixent, the pioneering biologic, has shown remarkable success in reducing symptoms and achieving disease remission in a pivotal study on bullous pemphigoid.

Nxera Pharma's collaborator Centessa reveals encouraging interim Phase 1 clinical results for their new OX2R agonist, ORX750, in healthy volunteers with acute sleep deprivation.

The U.S. FDA has approved TREMFYA® (guselkumab) for adults with moderate to severe ulcerative colitis, bolstering Johnson & Johnson's position in the inflammatory bowel disease market.

Beijing QL Biopharmaceutical revealed Phase 1c clinical results for its primary drug candidate ZT002 at the EASD Annual Meeting 2024.

Cytokinetics, Incorporated (Nasdaq: CYTK) disclosed that data from the Phase 1 clinical trial of CK-4021586 (CK-586) were showcased during a poster presentation at the ACCP Annual Meeting.

CytomX Therapeutics reports initial patient treatment with CX-801, a dual-masked Interferon-Alpha 2b PROBODY®, in a Phase 1 trial for solid tumor patients.

Zealand Pharma reveals encouraging top-line outcomes from a 13-week Phase 1b trial of their GLP-1/GLP-2 receptor dual agonist dapiglutide.